• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

7年期间重症患者中耐黏菌素或替加环素的产碳青霉烯酶肺炎克雷伯菌血流感染的分子流行病学及危险因素

Molecular epidemiology and risk factors for colistin- or tigecycline-resistant carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients during a 7-year period.

作者信息

Papadimitriou-Olivgeris Matthaios, Bartzavali Christina, Spyropoulou Aikaterini, Lambropoulou Anastasia, Sioulas Nektarios, Vamvakopoulou Sophia, Karpetas Georgios, Spiliopoulou Iris, Vrettos Theofanis, Anastassiou Evangelos D, Fligou Fotini, Christofidou Myrto, Marangos Markos

机构信息

Division of Infectious Diseases, Department of Internal Medicine, School of Medicine, University of Patras, 26504, Rion-Patras, Greece.

Department of Microbiology, School of Medicine, University of Patras, 26504, Rion-Patras, Greece.

出版信息

Diagn Microbiol Infect Dis. 2018 Nov;92(3):235-240. doi: 10.1016/j.diagmicrobio.2018.06.001. Epub 2018 Jun 7.

DOI:10.1016/j.diagmicrobio.2018.06.001
PMID:30076041
Abstract

A matched 1:2 case-control study was conducted among critically ill patients in order to identify the risk factors of colistin or tigecycline-resistant carbapenemase-producing Klebsiella pneumoniae (ColR-Kp, TigR-Kp) bacteraemia. MIC to colistin and tigecycline were determined by Etest. From 224 bacteraemic patients, 46.4% and 29.5% were resistant to colistin and tigecycline, respectively. PCR revealed that 199 isolates carried the bla gene. PCR revealed that no isolate carried the mcr-1 gene. Risk factors for ColR-Kp bacteraemia as compared to patients with bacteraemia by a colistin-susceptible isolate or patients without carbapenemase-producing K. pneumoniae bacteraemia were colistin or tigecycline administration and tracheostomy, while TigR-Kp bacteraemia as compared to either patients with bacteraemia by tigecycline-susceptible isolate or patients without carbapenemase-producing K. pneumoniae bacteraemia were colistin or tigecycline administration, number of comorbidities and prior bacteraemia by a Gram-negative pathogen. Administration of colistin and tigecycline predisposed to development of bacteraemia by either ColR-Kp or TigR-Kp.

摘要

为了确定耐黏菌素或替加环素的产碳青霉烯酶肺炎克雷伯菌(ColR-Kp、TigR-Kp)菌血症的危险因素,在重症患者中开展了一项1:2配对病例对照研究。采用Etest法测定对黏菌素和替加环素的最低抑菌浓度(MIC)。在224例菌血症患者中,分别有46.4%和29.5%对黏菌素和替加环素耐药。聚合酶链反应(PCR)显示199株分离菌携带bla基因。PCR显示没有分离菌携带mcr-1基因。与由对黏菌素敏感的分离菌引起菌血症的患者或无产碳青霉烯酶肺炎克雷伯菌菌血症的患者相比,ColR-Kp菌血症的危险因素是使用黏菌素或替加环素以及气管切开术;而与由对替加环素敏感的分离菌引起菌血症的患者或无产碳青霉烯酶肺炎克雷伯菌菌血症的患者相比,TigR-Kp菌血症的危险因素是使用黏菌素或替加环素、合并症数量以及既往革兰阴性病原体菌血症。使用黏菌素和替加环素易导致ColR-Kp或TigR-Kp菌血症的发生。

相似文献

1
Molecular epidemiology and risk factors for colistin- or tigecycline-resistant carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients during a 7-year period.7年期间重症患者中耐黏菌素或替加环素的产碳青霉烯酶肺炎克雷伯菌血流感染的分子流行病学及危险因素
Diagn Microbiol Infect Dis. 2018 Nov;92(3):235-240. doi: 10.1016/j.diagmicrobio.2018.06.001. Epub 2018 Jun 7.
2
Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit.重症监护病房中产KPC肺炎克雷伯菌血流感染患者的感染危险因素及死亡预测因素。
Scand J Infect Dis. 2014 Sep;46(9):642-8. doi: 10.3109/00365548.2014.923106. Epub 2014 Jul 14.
3
The role of colonization pressure in the dissemination of colistin or tigecycline resistant KPC-producing Klebsiella pneumoniae in critically ill patients.定植压力在重症患者中耐黏菌素或替加环素的产KPC肺炎克雷伯菌传播中的作用
Infection. 2014 Oct;42(5):883-90. doi: 10.1007/s15010-014-0653-x. Epub 2014 Jul 10.
4
Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients: risk factors and predictors of mortality.重症患者产碳青霉烯酶肺炎克雷伯菌血流感染:危险因素及死亡预测因素
Eur J Clin Microbiol Infect Dis. 2017 Jul;36(7):1125-1131. doi: 10.1007/s10096-017-2899-6. Epub 2017 Jan 19.
5
Characterization of ST258 Colistin-Resistant, blaKPC-Producing Klebsiella pneumoniae in a Greek Hospital.希腊一家医院中耐黏菌素、产blaKPC的肺炎克雷伯菌ST258的特征分析
Microb Drug Resist. 2016 Jul;22(5):392-8. doi: 10.1089/mdr.2015.0282. Epub 2016 Feb 3.
6
First report of NDM-1-producing Klebsiella pneumoniae imported from Africa to Italy: Evidence of the need for continuous surveillance.首次从非洲进口到意大利的携带 NDM-1 基因的肺炎克雷伯菌:需要持续监测的证据。
J Glob Antimicrob Resist. 2017 Mar;8:23-27. doi: 10.1016/j.jgar.2016.10.004. Epub 2016 Dec 5.
7
A ten-year surveillance study of carbapenemase-producing Klebsiella pneumoniae in a tertiary care Greek university hospital: predominance of KPC- over VIM- or NDM-producing isolates.希腊一家三级护理大学医院对产碳青霉烯酶肺炎克雷伯菌的十年监测研究:产KPC酶的分离株比产VIM酶或NDM酶的分离株更占优势。
J Med Microbiol. 2016 Mar;65(3):240-246. doi: 10.1099/jmm.0.000217. Epub 2015 Dec 23.
8
In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates.黏菌素联合其他抗菌药物对耐黏菌素产KPC肺炎克雷伯菌血流分离株的体外活性及抗生素后效应
J Antimicrob Chemother. 2014 Jul;69(7):1856-65. doi: 10.1093/jac/dku065. Epub 2014 Mar 19.
9
Outbreaks of colistin-resistant and colistin-susceptible KPC-producing Klebsiella pneumoniae in a Brazilian intensive care unit.巴西一家重症监护病房中出现对黏菌素耐药及对黏菌素敏感的产KPC肺炎克雷伯菌暴发情况。
J Hosp Infect. 2016 Dec;94(4):322-329. doi: 10.1016/j.jhin.2016.08.019. Epub 2016 Aug 26.
10
Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.在引入头孢他啶/阿维巴坦后,希腊 ICU 中产生碳青霉烯酶的肺炎克雷伯菌的流行情况从 blaKPC 到 blaVIM 携带株的逆转。
J Antimicrob Chemother. 2019 Jul 1;74(7):2051-2054. doi: 10.1093/jac/dkz125.

引用本文的文献

1
Risk Factors and Outcomes for Isolation with Polymyxin B-Resistant Enterobacterales from 2018-2022: A Case-Control Study.2018 - 2022年耐多黏菌素B肠杆菌科细菌分离的危险因素及结局:一项病例对照研究
Infect Drug Resist. 2023 Dec 22;16:7809-7817. doi: 10.2147/IDR.S435697. eCollection 2023.
2
Risk factors associated with colistin resistance in carbapenemase-producing Enterobacterales: a multicenter study from a low-income country.碳青霉烯酶-producing Enterobacterales 中与多粘菌素耐药相关的危险因素:来自低收入国家的一项多中心研究。
Ann Clin Microbiol Antimicrob. 2023 Aug 2;22(1):64. doi: 10.1186/s12941-023-00609-8.
3
Population pharmacokinetics of tigecycline in critically ill patients.
重症患者中替加环素的群体药代动力学。
Front Pharmacol. 2023 Mar 13;14:1083464. doi: 10.3389/fphar.2023.1083464. eCollection 2023.
4
Risk Factors for Colistin-Resistant Carbapenem-Resistant in the Postacute Care Setting.急性后期护理环境中耐黏菌素碳青霉烯类耐药菌的危险因素。
Open Forum Infect Dis. 2022 Sep 2;9(9):ofac452. doi: 10.1093/ofid/ofac452. eCollection 2022 Sep.
5
Genomic Epidemiology of Carbapenemase-Producing and Colistin-Resistant among Sepsis Patients in Ethiopia: a Whole-Genome Analysis.埃塞俄比亚败血症患者中产碳青霉烯酶和多粘菌素耐药菌的基因组流行病学:全基因组分析。
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0053422. doi: 10.1128/aac.00534-22. Epub 2022 Jul 25.
6
Polyclonal Endemicity of Carbapenemase-Producing in ICUs of a Greek Tertiary Care Hospital.希腊一家三级护理医院重症监护病房中产碳青霉烯酶菌的多克隆地方性流行情况。
Antibiotics (Basel). 2022 Jan 25;11(2):149. doi: 10.3390/antibiotics11020149.
7
Drug Susceptibility and Molecular Epidemiology of Bloodstream Infection in ICU Patients in Shanghai, China.中国上海重症监护病房患者血流感染的药物敏感性与分子流行病学
Front Med (Lausanne). 2021 Oct 13;8:754944. doi: 10.3389/fmed.2021.754944. eCollection 2021.
8
Risk Factors and Outcomes of Infection Before and After Allogeneic Hematopoietic Cell Transplantation.异基因造血细胞移植前后感染的危险因素及结局
Front Med (Lausanne). 2021 Feb 4;7:608165. doi: 10.3389/fmed.2020.608165. eCollection 2020.
9
Characteristics of Carbapenemase-Producing Isolated in the Intensive Care Unit of the Largest Tertiary Hospital in Bangladesh.孟加拉国最大的三级医院重症监护病房中产碳青霉烯酶分离株的特征
Front Microbiol. 2021 Jan 15;11:612020. doi: 10.3389/fmicb.2020.612020. eCollection 2020.
10
Impact of Tigecycline's MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing Bacteraemia Treated with Tigecycline Monotherapy-Validation of 2019's EUCAST Proposed Breakpoint Changes.替加环素的最低抑菌浓度对接受替加环素单药治疗的产碳青霉烯酶菌血症重症患者预后的影响——2019年欧洲抗菌药物敏感性试验委员会(EUCAST)建议的折点变化验证
Antibiotics (Basel). 2020 Nov 19;9(11):828. doi: 10.3390/antibiotics9110828.